We develop novel disease modifying drugs.

Our mission is a simple question we ask ourselves — can we slow down or stop neurodegeneration when treating chronic neurological diseases?

Enterprise Estonia have confirmed their support for an Applied Research Program to develop a small molecule Glial cell line – Derived Neurotrophic Factor (GDNF) mimetics, for the treatment of Parkinson’s Disease and other indications.

Funded as part of the Union’s response to the COVID-19 pandemic.

We partner with various internationally well-known leading scientists in areas of biomedicine, who have numerous credits to their scientific work.

50+

patents / families

600+

publications

30,000+

citations